RemeGen Co., Ltd. is a biopharmaceutical company engaged in the discovery, development, production, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases. The company’s product portfolio includes Telitacicept (RC18), a dual-target biological drug for systemic lupus erythematosus, Sjögren's syndrome, and IgA nephropathy, and Disitamab Vedotin (RC48), an antibody-drug conjugate for HER2-positive cancers. Its pipeline features candidates such as RC28, RC88, RC148, and RC278. RemeGen serves markets in China and globally, with R&D centers and offices located in China and the United States. The company was co-founded in 2008 by Wang Weidong and Jianmin Fang. Key subsidiaries include RemeGen Medical Research (Shanghai) Co., Ltd., RemeGen Biosciences, Inc., RemeGen Hong Kong Limited, and Ruimeijing (Beijing) Pharmaceutical Technology Co., Ltd.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage remegen.com
Sector Healthcare IR page remegen.com
Tags
biologics, autoimmune diseases, oncology, ophthalmology, antibody-drug conjugates, bispecific antibodies, systemic lupus erythematosus, iga nephropathy, sjögren's syndrome, her2-positive cancer, Telitacicept, RC18, Disitamab Vedotin, RC48, RC28, RC88, RC148, RC278, RemeGen Medical Research (Shanghai) Co. Ltd., RemeGen Biosciences Inc., RemeGen Hong Kong Limited, Ruimeijing (Beijing) Pharmaceutical Technology Co. Ltd.
Press page —

Metrics

Valuation  
Market cap HK$ 33.261B
Market cap (USD) $ 4.239B
P/E 41.87
PEG —
P/BV 3.40
P/S 3.53
P/OCF 6.26
P/FCF —
Dividend yield —
Turnover / mcap 0.30%
Returns  
ROE 25.4%
ROI 14.1%
ROIC 14.1%
Profit margin 21.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 1.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 3.242B 1.71B 1.076B 767.775M 1.424B 0 —
Net profit 709.65M -1.468B -1.511B -998.83M 276.258M -697.821M -430.28M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 86.38 10.99 21.77 51.19 92.64 100.86 —
Price performance 12m 7.04 -0.49 -0.6 -0.47 -0.01 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Remegen Co., Ltd. (ticker 9995), listed in Hong Kong.

ETFs Holding Remegen Co., Ltd.

ETF Weight in ETF Shares Market value As of
DFEM 0.02% 172,500 $ 1.525M Nov 12, 2026
AVEM 0.01% 292,000 $ 2.345M Nov 16, 2026
DFAE 0.01% 69,500 $ 614.409K Nov 12, 2026
DFAX 0.00% 23,500 $ 207.75K Nov 12, 2026